|drug2638||Presatovir placebo Wiki||0.71|
|D012327||RNA Virus Infections NIH||0.29|
|D018357||Respiratory Syncytial Virus Infections NIH||0.25|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
In late December 2019, a new coronavirus strain emerged causing coronavirus disease 2019 (COVID19). Since then, COVID19 has become a global pandemic outbreak being declared a "public health emergency of international concern" by the International Health Regulations Emergency Committee of the WHO on January 30, 2020. Several emergency measures have been implemented in different countries such as lockdown, social distancing, and testing. The pandemic concerns to public worldwide but also to couples aiming to conceive through natural means or undergoing assisted reproductive technologies (ART). The American Society of Reproductive Medicine (ASRM) as well as European Society of Human Reproduction and Embryology (ESHRE) have recommend a precautionary approach and advise that all fertility patients considering or planning treatment, even if they do not meet the diagnostic criteria for COVID-19 infection, should avoid becoming pregnant at this time until more is known about the virus. Therefore, new cycles for infertility patients as well as non-medically urgent gamete preservation treatments, such as social egg freezing, have been suspended deferring embryo transfer in those patients with initiated cycles. In this moment, when reopening phases are being undertaken in most countries, the decision to resume the In vitro fertilization (IVF) treatment in a safe environment to the healthcare workers and patients is the biggest concern of the ART clinics. The present study aims to describe the percentage of COVID-19 condition (naïve, immune, and currently infected) in asymptomatic individuals from two different ART centres. For this purpose, the ART centres' personnel and patients will be tested for COVID-19 before resume the clinic daily routine just after the lockdown period.
Description: Statistical quantification of the prevalence of contagiousness in asymptomatic individuals attending IVF clinics in the USA based on the gold standard test (PCR).Measure: Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs Time: 2 months
Description: Statistical quantification of the rate of immunized (IgG) individuals attending to IVF clinics in the USA based on the ELISA test.Measure: Ratio of asymptomatic immunized (IgG) population Time: 2 months
Description: To validate the use of saliva specimen as a possible substitute to nasopharyngeal swabs, offering a simpler, easily self-sampling and large-scale test.Measure: To validate saliva specimens as a biological sample for COVID-19 testing Time: 2 months
Description: Age, gender and location distribution of affected contagious individuals in two areas of the USA with different pandemic status.Measure: Description of demographic characteristics Time: 2 months
This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
Description: TaqPath RT-PCR assay performed on saliva compared to TaqPath RT-PCR performed on nasopharyngeal samples for assay accuracy, concordance, reproducibility/precision, analytical sensitivity and analytical specificity.Measure: Detection of COVID-19 SARs-CoV-2 in saliva samples versus nasopharyngeal samples Time: up to 7 days
Description: Participants may be recruited from individuals presenting for various indications for testing including; followup testing after previous positive result, at risk healthcare worker, exposure to known positive or symptomatic, public facing worker or workplace hazards, employee based screening.Measure: Reason for testing Time: Baseline
Description: Participant is symptomatic or asymptomaticMeasure: Current symptom status Time: Baseline
Description: Participant reports one or more of the following symptoms at baseline. Cough, Shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, any nausea, vomiting or diarrhea.Measure: Current symptoms Time: Baseline
Description: Participant reports one or more of the following symptoms at baseline. Cough, Shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, any nausea, vomiting or diarrhea.Measure: Prior symptoms Time: Baseline
Description: Participant reports date of first symptom or number of days since first symptom.Measure: Date of first symptom or number of days since first symptom. Time: Baseline
Description: Participant reported result (positive, negative, inconclusive) of previous test for COVID-19 and date of test .Measure: Previous test for COVID-19 and date of test. Time: Baseline
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports